|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
IL-6 is a key proinflammatory cytokine contributing to lymphocyte and plasmacyte maturation and to atherosclerosis and aneurysm development.
|
28434701 |
2018 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
This study aimed to evaluate the potential effects and molecular mechanisms of IL-6 blocker, tocilizumab, in atherosclerosis with diabetes.
|
30383519 |
2018 |
|
Atherosclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
A total of 4833 stable atherosclerosis patients in the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS) had IL-6 levels measured before randomization and after treatment with placebo or one of three doses of canakinumab (50 mg, 150 mg, or 300 mg) given subcutaneously once every 3 months.
|
30165610 |
2018 |
|
Atherosclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In summary, our data reveal that in contrast to young MSCs, MSCs from elderly individuals with ATH secrete high levels of IL-6, IL-8/CXCL8 and MCP-1/CCL2 which mediate their reduced immunopotency.
|
28194905 |
2017 |
|
Atherosclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Among participants without CAD history who underwent CCTA, patients with high level of IL-6 had increased burden of atherosclerosis and higher MACE risk compared to participants of low level of IL-6.
|
28233119 |
2017 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Performance of serum IL-6 assay was compared with ACC/AHA atherosclerotic cardiovascular disease (ASCVD) risk score and hs-CRP through receiver operating characteristic (ROC) curves.
|
28878828 |
2017 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Interleukin-6 and plasminogen activator inhibitor-1 did not provide incremental value to fibrinogen when examining the associations with degree of atherosclerosis.
|
27755007 |
2017 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
In multivariate analysis, OR for subclinical atherosclerosis was 7 (95% CI, 1.3-40, P = 0.02) and 9 (95% CI, 1.0-85, P = 0.04) for patients older than 44 years and IL-6 > 6·6 pg/mL, respectively.
|
28664622 |
2017 |
|
Atherosclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In addition, real-time quantitative RT-PCR analyses showed that the apoA-I infusions decreased the mRNA levels of two pro-inflammatory molecules, i.e. nuclear factor kappa B (NF-κB) and cyclooxygenase-2 (COX-2), in aorta of AS rabbits, which was associated with a concomitant reduction in endothelial VCAM-1 and IL-6 mRNA transcription.
|
28069582 |
2017 |
|
Atherosclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The aim of the present study was to explore the relationship between miR-29b and IL-6 and to test whether circulating levels of miR-29b and IL-6 could predict atherosclerosis.
|
29197872 |
2017 |
|
Atherosclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
SP-D deficiency reduces atherosclerosis in part by decreasing the accumulation and proliferation of macrophages and by reducing IL-6 levels systemically.
|
28472244 |
2017 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
IL-6 may have a role in aberrant differentiation of VSCs contributing to vascular calcification in atherosclerosis.
|
26840742 |
2016 |
|
Atherosclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, inflammatory factor IL‑6 may participate in the pathogenesis of atherosclerosis by increasing EL expression and the proliferation of endothelial cells via the p38 MAPK and NF-κB signaling pathways.
|
27430252 |
2016 |
|
Atherosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our findings support a role for the interleukin-6-174G>C polymorphism in increased risk of atherosclerosis in individuals with chronic stress.
|
24630186 |
2014 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Moreover, miR-144-3p mimics (agomir) enhanced the expression of inflammatory factors, including IL-1β, IL-6 and TNF-α, in vivo and in vitro, inhibited cholesterol efflux in THP-1 macrophage-derived foam cells, decreased HDL-C circulation and impaired RCT in vivo, resulting in accelerated pathological progression of atherosclerosis in apoE-/- mice.
|
24733347 |
2014 |
|
Atherosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The crude odds ratios (ORs) and their corresponding 95% confidence intervals (CIs) were used to estimate the association between the IL-6 gene -174G>C polymorphism and atherosclerosis ( AS ) risk.
|
23954871 |
2013 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
The purpose of our study was to investigate the effects of endothelial lipase gene polymorphism and inflammation markers (CRP, IL-1β, IL-6, IL-8 and TNF-α) in the atherosclerosis.
|
23673478 |
2013 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
These results demonstrate the differential expression of SOCS1 and SOCS3 in atherosclerosis and suggest that SOCS3, together with IL-6 may promote the formation and development of atherosclerosis.
|
23545584 |
2013 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
These deficits are not associated with atherosclerosis but are accompanied with altered astroglial activation, neurogenesis, cyclooxygenase-2 immunoreactivity and increased plasma IL-6.
|
23957944 |
2013 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Chronic administration of LPS in ApoE(-/-) mice significantly increased the expression of inflammatory cytokines (TNF-α, IL-1β, IL-6, and MCP-1), increased infiltration of inflammatory cells, and enhanced the development of atherosclerosis.
|
23564081 |
2013 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
We investigated the relationship of IL-6 and P4Hα1 in atherosclerosis-prone mice and human aortic smooth muscle cells (HASMCs).
|
23022409 |
2012 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
In the present study, we showed that treatment with a fusion protein of the natural IL-6 transsignaling inhibitor soluble glycoprotein 130 (sgp130) and IgG1-Fc (sgp130Fc) dramatically reduced atherosclerosis in hypercholesterolemic Ldlr(-/-) mice without affecting weight gain and serum lipid levels.
|
22075248 |
2012 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
It can also be protective in CAD patients since the reduced adiponectin-induced IL-6 release in CAD macrophages compared to controls, could be beneficial in the development of inflammation related atherosclerosis.
|
21626471 |
2011 |
|
Atherosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our results support a role of IL6 -174 gene polymorphism in the development of subclinical atherosclerosis in patients with RA.
|
20149313 |
2010 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
We hypothesized a possible mechanism for atherosclerosis in which interleukin-6 (IL-6) might affect the endothelial nitric oxide synthase (eNOS)-caveolin-1 interaction and result in decreased nitric oxide bioavailability in the setting of low-grade inflammation.
|
20375905 |
2010 |